Currently out of the existing stock ratings of Daniel Busby, 8 are a BUY (72.73%), 3 are a HOLD (27.27%).

Daniel Busby

Work Performance Price Targets & Ratings Chart

Analyst Daniel Busby, carries an average stock price target met ratio of 56.25% that have a potential upside of 22.76% achieved within 120 days.

Daniel Busby’s has documented 27 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VRCA, Verrica Pharmaceuticals at 15-Aug-2024.

Wall Street Analyst Daniel Busby

Analyst best performing recommendations are on MNKD (MANNKIND CORP).
The best stock recommendation documented was for MNKD (MANNKIND CORP) at 5/13/2021. The price target of $5 was fulfilled within 46 days with a profit of $0.97 (24.07%) receiving and performance score of 5.23.

Average potential price target upside

VRCA Verrica Pharmaceuticals JAZZ Jazz Pharmaceuticals PLC MNKD MannKind Corp PFE Pfizer

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 18-Dec-2025

$17

$12.62 (288.13%)

3 months 15 days ago
(18-Dec-2025)

0/2 (0%)

$8.89 (109.62%)

Hold Since 03-Oct-2024

10 months 19 days ago
(14-May-2025)

1/4 (25%)

$95.7 (113.52%)

253

Hold Since 06-Nov-2024

11 months 25 days ago
(08-Apr-2025)

0/13 (0%)

$45.1 (47.52%)

Buy Since 22-Mar-2023

$30

$25.62 (584.93%)

$120

1 years 2 months 27 days ago
(06-Jan-2025)

0/3 (0%)

$23.26 (345.10%)

Hold Since 05-Nov-2024

1 years 4 months 28 days ago
(05-Nov-2024)

1/3 (33.33%)

$1032.9 (1539.34%)

79

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Daniel Busby?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?